BPC-157
Research OnlyA synthetic peptide derived from human gastric juice protein. Preclinical studies suggest tissue repair properties, but human clinical trial data is extremely limited. A 2025 systematic review of 36 studies found only 1 clinical study.
Body Protection Compound-157 · Bepecin · PL 14736 · PL-10
3 human studies
- Preclinical
- 91%
- Clinical
- 9%
Based on 32 cited sources
community-reported · not clinically demonstrated · very-low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth: only human data is one retrospective uncontrolled case series (7/12 knee-pain patients, intra-articular) plus a halted PL-14736 Phase 2, atop an extensive but single-group-dominated preclinical program. Mechanism: multiple animal-mapped pathways (VEGFR2, FAK-paxillin, NO) but no validated receptor/binding target. Plausibility: coherent angiogenesis/ cytoprotection chain, capped by implausibly broad cross-injury claims. Global Coverage: literature clusters around Sikiric (Croatia) with limited Taiwan replication; no regulatory approval. Community Experience: very large, >7yr sustained r/Peptides "Wolverine Stack" use, broadly consistent, only minor adverse reports. Effectiveness basis community-reported (no clinical efficacy estimate; the lone case series is uncontrolled self-report), Very Low confidence, capped at 50.
The proposed mechanisms of BPC-157 are based primarily on animal and in vitro studies. Human mechanistic data is lacking.
How It Works (Simplified)
BPC-157 appears to act as a “repair signal” through several pathways:
Promotes new blood vessel formation via VEGF/VEGFR2 pathway activation, improving nutrient delivery to healing tissues.
Activates FAK-paxillin pathway, helping repair cells move to injury sites and attach to healing tissue.
Modulates nitric oxide system - upregulating beneficial vasodilation while reducing inflammatory damage.
Protects gut lining and other tissues from damage, particularly from NSAIDs and other stressors.
Key Research: Hsieh MJ et al. (Taiwan, 2017) demonstrated VEGFR2 activation in ischemic models. PMID:27847966
Important Limitations
- Nearly all mechanistic studies from single research group (Croatian)
- Translation to human physiology is unconfirmed
- Optimal administration route for systemic effects unknown
- Bioavailability and pharmacokinetics in humans not characterized
Net effect.May accelerate wound and tissue healing — supported by rodent models; no human studies.
Net effect.May improve tendon and ligament repair — animal and in-vitro evidence only.
Reported positives
- Accelerated tendon and ligament healing frequently reported
- Reduced joint pain and inflammation within days
- Gut healing and reduced IBS symptoms cited
- Faster recovery from injuries and surgery
Reported negatives
- Inconsistent product quality from research suppliers
- Some users report increased anxiety or restlessness
- Effects diminish after extended use
- Injection site reactions with subcutaneous administration
“One of the most discussed peptides in r/Peptides. Often stacked with TB-500 as the "Wolverine Stack."”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
- 001
The literature clusters around a single research group. The large majority of BPC-157 publications originate from one laboratory (Sikirić and collaborators), and independent replication remains limited.
- 002
No specific receptor has been identified. Despite many proposed pathways (VEGFR2, nitric oxide, growth-factor cross-talk), no defined molecular target for BPC-157 has been established.
- 003
The PL-14736 Phase 2 trial was halted before completion, and no pivotal human efficacy trial has since been completed and published.
- 004
Effect sizes in some rodent papers strain biological plausibility, with near-universal benefit across unrelated injury models.
- 005
Long-term safety is genuinely unstudied in humans. There are no controlled data on chronic administration, drug interactions, or oncological risk.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| NCT02637284 | Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of PL 14736 in Healthy Male Subjects Healthy Volunteers | BPC-157 | Phase 1 | Unknown | Feb 2016 |
| PLIVA-IBD-Trials | Multiple Phase I/II trials for IBD (PL-10, PLD-116) | BPC-157 | Phase 1-2 | Completed but unpublished | - |
| NCT07437547 | BPC 157 for Acute Hamstring Muscle Strain Repair Hamstring Muscle Strain, Skeletal Muscle Injury | BPC-157 | Phase 2 | Recruiting | Feb 2027 |
Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of PL 14736 in Healthy Male Subjects
Multiple Phase I/II trials for IBD (PL-10, PLD-116)
BPC 157 for Acute Hamstring Muscle Strain Repair
Based on preclinical observations: Initial angiogenic signaling may begin. Animal studies show early VEGF/VEGFR2 pathway activation within days of administration. No human timeline data available.
PMID:27847966Animal studies suggest ongoing tissue repair processes. In rat tendon models, improved collagen organization observed by 2-4 weeks. Gastric healing acceleration noted in ulcer models within this timeframe.
PMID:21030672Preclinical models show continued tissue remodeling. Rat studies demonstrated improved biomechanical properties of healing tendons. Muscle injury models showed functional recovery improvements.
PMID:25415472Long-term animal studies suggest sustained effects on tissue repair pathways. However, human pharmacokinetics, duration of effect, and optimal treatment length are completely unknown.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
TB-500
SynergisticCommonly combined in research for tissue repair. BPC-157's angiogenic and cytoprotective mechanisms may complement TB-500's actin-regulating and cell migration effects. No direct clinical studies on combination.
GHK-Cu
CompatibleDifferent mechanisms of action (BPC-157 systemic cytoprotection vs GHK-Cu copper-mediated signaling). No known contraindications; both target wound healing pathways through distinct routes.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while Thymosin Alpha-1 modulates immune function. Theoretical complementary benefits for recovery.
LL-37
CompatibleLL-37's antimicrobial properties may complement BPC-157's tissue repair effects in wound healing contexts. No interaction studies available.
Semaglutide
CautionBoth affect GI function. BPC-157 is gastroprotective while semaglutide slows gastric emptying. Unclear if effects interact; monitor GI symptoms if combined.
Melanotan-II
CautionBoth act on various receptor systems. Limited data on interactions. Exercise caution due to lack of combined safety data.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare BPC-157
Related Peptides
Cartalax
AED peptide · Ala-Glu-Asp · cartilage bioregulator
A synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.
GHK
Glycyl-Histidyl-Lysine · GHK tripeptide · Liver cell growth factor
A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
Sigumir
Cartilage cytamin · Joint peptides · A-6 cartilage peptides
A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Related Content
TB-500
Repair & Recovery · moderate evidence
GHK-Cu
Repair & Recovery · moderate evidence
What is BPC-157?
An introduction to BPC-157, its origins, claims, and importa...
BPC-157 vs Chonluten
View side-by-side analysis
BPC-157 vs GHK-Cu vs TB-500
View side-by-side analysis